Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 296

1.

124I Positron Emission Tomography/Computed Tomography Versus Conventional Radioiodine Imaging in Differentiated Thyroid Cancer: A Review.

Wu D, Ylli D, Heimlich SL, Burman KD, Wartofsky L, Van Nostrand D.

Thyroid. 2019 Sep 27. doi: 10.1089/thy.2018.0598. [Epub ahead of print]

PMID:
31452449
2.

Nationwide survey of implementation of 2011 Nuclear Regulatory Commission policy on release of patients after 131I therapy.

Wu D, Gomes-Lima CJ, Bloom G, Burman KD, Wartofsky L, Van Nostrand D.

J Nucl Med. 2019 Aug 26. pii: jnumed.119.230730. doi: 10.2967/jnumed.119.230730. [Epub ahead of print]

PMID:
31451488
3.

Clinical, Pathological, and Molecular Profiling of Radioactive Iodine Refractory Differentiated Thyroid Cancer.

Shobab L, Gomes-Lima C, Zeymo A, Feldman R, Jonklaas J, Wartofsky L, Burman KD.

Thyroid. 2019 Sep;29(9):1262-1268. doi: 10.1089/thy.2019.0075.

PMID:
31319763
4.

Improved Survival After Multimodal Approach with 131I Treatment in Patients with Bone Metastases Secondary to Differentiated Thyroid Cancer.

Wu D, Gomes Lima CJ, Moreau SL, Kulkarni K, Zeymo A, Burman KD, Wartofsky L, Van Nostrand D.

Thyroid. 2019 Jul;29(7):971-978. doi: 10.1089/thy.2018.0582. Epub 2019 May 30.

PMID:
31017051
5.

Cardiovascular Safety Trials for All New Diabetes Mellitus Drugs?

Low Wang CC, Everett BM, Burman KD, Wilson PWF.

Circulation. 2019 Apr 2;139(14):1741-1743. doi: 10.1161/CIRCULATIONAHA.118.038771. No abstract available.

PMID:
30933621
6.

Brain Metastases From Differentiated Thyroid Carcinoma: Prevalence, Current Therapies, and Outcomes.

Gomes-Lima CJ, Wu D, Rao SN, Punukollu S, Hritani R, Zeymo A, Deeb H, Mete M, Aulisi EF, Van Nostrand D, Jonklaas J, Wartofsky L, Burman KD.

J Endocr Soc. 2018 Nov 21;3(2):359-371. doi: 10.1210/js.2018-00241. eCollection 2019 Feb 1.

7.

Molecular aberrations and signaling cascades implicated in the pathogenesis of anaplastic thyroid cancer.

Saini S, Maker AV, Burman KD, Prabhakar BS.

Biochim Biophys Acta Rev Cancer. 2018 Dec 31. pii: S0304-419X(18)30141-0. doi: 10.1016/j.bbcan.2018.12.003. [Epub ahead of print] Review.

PMID:
30605717
8.

Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study.

Steward DL, Carty SE, Sippel RS, Yang SP, Sosa JA, Sipos JA, Figge JJ, Mandel S, Haugen BR, Burman KD, Baloch ZW, Lloyd RV, Seethala RR, Gooding WE, Chiosea SI, Gomes-Lima C, Ferris RL, Folek JM, Khawaja RA, Kundra P, Loh KS, Marshall CB, Mayson S, McCoy KL, Nga ME, Ngiam KY, Nikiforova MN, Poehls JL, Ringel MD, Yang H, Yip L, Nikiforov YE.

JAMA Oncol. 2019 Feb 1;5(2):204-212. doi: 10.1001/jamaoncol.2018.4616.

9.

Detection at Public Facilities of 131I in Patients Treated for Differentiated Thyroid Cancer: Frequency, Sites, Management by Security Agents, and Physician Documentation Recommended for Patients.

Bikas A, Wu D, Bethancourt E, Orquiza M, Bloom G, Burman KD, Wartofsky L, Van Nostrand D.

J Nucl Med. 2019 May;60(5):638-643. doi: 10.2967/jnumed.118.213256. Epub 2018 Oct 25.

PMID:
30361377
10.

Therapeutic advances in anaplastic thyroid cancer: a current perspective.

Saini S, Tulla K, Maker AV, Burman KD, Prabhakar BS.

Mol Cancer. 2018 Oct 23;17(1):154. doi: 10.1186/s12943-018-0903-0. Review.

11.

Poor patient compliance with instructions for continuous sialogogues after 131 I therapy.

Wu D, Khorjekar G, Kharazi P, Moreau S, Kulkarni K, Burman KD, Wartofsky L, Van Nostrand D.

Oral Dis. 2019 Jan;25(1):158-163. doi: 10.1111/odi.12969. Epub 2018 Sep 19.

PMID:
30169900
12.

Synchronous Independent Papillary Thyroid Carcinomas in Struma Ovarii and the Thyroid Gland With Different RAS Mutations.

Gomes-Lima CJ, Nikiforov YE, Lee W, Burman KD.

J Endocr Soc. 2018 Jul 10;2(8):944-948. doi: 10.1210/js.2018-00132. eCollection 2018 Aug 1.

13.

Reverse T3 or perverse T3? Still puzzling after 40 years.

Gomes-Lima C, Burman KD.

Cleve Clin J Med. 2018 Jun;85(6):450-455. doi: 10.3949/ccjm.85a.17079. No abstract available.

14.

Use of 99mTc-sestamibi SPECT/CT when conventional imaging studies are negative for localizing suspected recurrence in differentiated thyroid cancer: a method and a lesson for clinical management.

Wu D, Ylli D, Gomes Lima CJ, Lee W, Burman KD, Wartofsky L, Van Nostrand D.

Endocrine. 2018 Oct;62(1):57-63. doi: 10.1007/s12020-018-1636-y. Epub 2018 May 24.

PMID:
29797211
15.

Eliminating the Age Cutoff in Staging of Differentiated Thyroid Cancer: The Safest Road?

Ylli D, Burman KD, Van Nostrand D, Wartofsky L.

J Clin Endocrinol Metab. 2018 May 1;103(5):1813-1817. doi: 10.1210/jc.2017-02725.

PMID:
29741712
16.

Thrombosis in Thyroid Cancer.

Ordookhani A, Motazedi A, Burman KD.

Int J Endocrinol Metab. 2017 Oct 31;16(1):e57897. doi: 10.5812/ijem.57897. eCollection 2018 Jan. Review.

17.

Novel biomarker SYT12 may contribute to predicting papillary thyroid cancer outcomes.

Jonklaas J, Murthy S, Liu D, Klubo-Gwiezdzinska J, Krishnan J, Burman KD, Boyle L, Carrol N, Felger E, Loh YP.

Future Sci OA. 2017 Sep 22;4(1):FSO249. doi: 10.4155/fsoa-2017-0087. eCollection 2018 Jan.

18.

Stable Isotope Pharmacokinetic Studies Provide Insight into Effects of Age, Sex, and Weight on Levothyroxine Metabolism.

Younis IR, Ahmed MA, Burman KD, Soldin OP, Jonklaas J.

Thyroid. 2018 Jan;28(1):41-49. doi: 10.1089/thy.2017.0380. Epub 2018 Jan 2.

19.

Hemostasis in Overt and Subclinical Hyperthyroidism.

Ordookhani A, Burman KD.

Int J Endocrinol Metab. 2017 Apr 23;15(3):e44157. doi: 10.5812/ijem.44157. eCollection 2017 Jul. Review.

20.

Selected Radiation Safety Aspects Including Transportation and Lodging After Outpatient 131I Therapy for Differentiated Thyroid Cancer.

Gomes-Lima CJ, Wu D, Kharazi PH, Khojekar GJ, Ringel MD, Vetter RJ, Bloom G, Burman KD, Wartofsky L, Van Nostrand D.

Thyroid. 2017 Dec;27(12):1558-1565. doi: 10.1089/thy.2017.0124.

PMID:
29132255
21.

Hemostasis in Hypothyroidism and Autoimmune Thyroid Disorders.

Ordookhani A, Burman KD.

Int J Endocrinol Metab. 2017 Mar 9;15(2):e42649. doi: 10.5812/ijem.42649. eCollection 2017 Apr. Review.

22.

Randomized Trial Comparing Two Algorithms for Levothyroxine Dose Adjustment in Pregnant Women With Primary Hypothyroidism.

Sullivan SD, Downs E, Popoveniuc G, Zeymo A, Jonklaas J, Burman KD.

J Clin Endocrinol Metab. 2017 Sep 1;102(9):3499-3507. doi: 10.1210/jc.2017-01086.

PMID:
28911144
23.

Amifostine does not protect thyroid cancer cells in DNA damaging in vitro models.

Klubo-Gwiezdzinska J, Costello J Jr, Jensen K, Patel A, Tkavc R, Van Nostrand D, Burman KD, Wartofsky L, Vasko V.

Endocr Connect. 2017 Oct;6(7):469-478. doi: 10.1530/EC-17-0138. Epub 2017 Aug 8.

24.

Iodine deficiency: Clinical implications.

Niwattisaiwong S, Burman KD, Li-Ng M.

Cleve Clin J Med. 2017 Mar;84(3):236-244. doi: 10.3949/ccjm.84a.15053. Review.

25.

WHAT IS THE CLINICAL ROLE OF ORAL LIQUID PREPARATIONS IN THE TREATMENT OF PATIENTS WITH HYPOTHYROIDISM?

Burman KD, Braverman LE.

Endocr Pract. 2017 Feb;23(2):243-244. doi: 10.4158/EP161705.CO. Epub 2017 Jan 17. No abstract available.

PMID:
28095045
26.

18F-FDG-PET SUV AS A PROGNOSTIC MARKER OF INCREASING SIZE IN THYROID CANCER TUMORS.

Singh I, Bikas A, Garcia CA, Desale S, Wartofsky L, Burman KD.

Endocr Pract. 2017 Feb;23(2):182-189. doi: 10.4158/EP161390.OR. Epub 2016 Nov 16.

PMID:
27849386
27.

Targeted therapies in thyroid cancer: an extensive review of the literature.

Bikas A, Vachhani S, Jensen K, Vasko V, Burman KD.

Expert Rev Clin Pharmacol. 2016 Oct;9(10):1299-1313. doi: 10.1080/17512433.2016.1204230. Epub 2016 Jul 15.

PMID:
27367142
28.
29.

Thyroid Nodules.

Burman KD, Wartofsky L.

N Engl J Med. 2016 Mar 31;374(13):1294-5. doi: 10.1056/NEJMc1600493. No abstract available.

PMID:
27028927
30.

A 2015 Survey of Clinical Practice Patterns in the Management of Thyroid Nodules.

Burch HB, Burman KD, Cooper DS, Hennessey JV, Vietor NO.

J Clin Endocrinol Metab. 2016 Jul;101(7):2853-62. doi: 10.1210/jc.2016-1155. Epub 2016 Mar 25.

PMID:
27014951
31.

Effects of Dosimetrically Guided I-131 Therapy on Hematopoiesis in Patients With Differentiated Thyroid Cancer.

Bikas A, Schneider M, Desale S, Atkins F, Mete M, Burman KD, Wartofsky L, Van Nostrand D.

J Clin Endocrinol Metab. 2016 Apr;101(4):1762-9. doi: 10.1210/jc.2015-3544. Epub 2016 Feb 22.

32.

Phase 2 clinical trial of sunitinib as adjunctive treatment in patients with advanced differentiated thyroid cancer.

Bikas A, Kundra P, Desale S, Mete M, O'Keefe K, Clark BG, Wray L, Gandhi R, Barett C, Jelinek JS, Wexler JA, Wartofsky L, Burman KD.

Eur J Endocrinol. 2016 Mar;174(3):373-80. doi: 10.1530/EJE-15-0930. Epub 2015 Dec 15.

PMID:
26671977
33.

CLINICAL PRACTICE. Thyroid Nodules.

Burman KD, Wartofsky L.

N Engl J Med. 2015 Dec 10;373(24):2347-56. doi: 10.1056/NEJMcp1415786. Review. No abstract available.

PMID:
26650154
34.

Metformin Attenuates 131I-Induced Decrease in Peripheral Blood Cells in Patients with Differentiated Thyroid Cancer.

Bikas A, Van Nostrand D, Jensen K, Desale S, Mete M, Patel A, Wartofsky L, Vasko V, Burman KD.

Thyroid. 2016 Feb;26(2):280-6. doi: 10.1089/thy.2015.0413. Epub 2015 Dec 30.

35.

Glucose-deprivation increases thyroid cancer cells sensitivity to metformin.

Bikas A, Jensen K, Patel A, Costello J Jr, McDaniel D, Klubo-Gwiezdzinska J, Larin O, Hoperia V, Burman KD, Boyle L, Wartofsky L, Vasko V.

Endocr Relat Cancer. 2015 Dec;22(6):919-32. doi: 10.1530/ERC-15-0402. Epub 2015 Sep 11.

PMID:
26362676
36.

Evaluation of Thyroid Bed Nodules on Ultrasonography after Total Thyroidectomy: Risk for Loco-Regional Recurrence of Thyroid Cancer.

Choudhary C, Wartofsky L, Tefera E, Burman KD.

Eur Thyroid J. 2015 Jun;4(2):106-14. doi: 10.1159/000431317. Epub 2015 Jun 11.

37.

Endocrine Changes in Obesity.

Sidhu S, Parikh T, Burman KD.

In: Feingold KR, Anawalt B, Boyce A, Chrousos G, Dungan K, Grossman A, Hershman JM, Kaltsas G, Koch C, Kopp P, Korbonits M, McLachlan R, Morley JE, New M, Perreault L, Purnell J, Rebar R, Singer F, Trence DL, Vinik A, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-.
2017 Oct 12.

38.

A 2013 European survey of clinical practice patterns in the management of Graves' disease.

Bartalena L, Burch HB, Burman KD, Kahaly GJ.

Clin Endocrinol (Oxf). 2016 Jan;84(1):115-20. doi: 10.1111/cen.12688. Epub 2015 Jan 9.

PMID:
25581877
39.

Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement.

Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, Cooper DS, Kim BW, Peeters RP, Rosenthal MS, Sawka AM; American Thyroid Association Task Force on Thyroid Hormone Replacement.

Thyroid. 2014 Dec;24(12):1670-751. doi: 10.1089/thy.2014.0028.

40.

Single-dose T3 administration: kinetics and effects on biochemical and physiological parameters.

Jonklaas J, Burman KD, Wang H, Latham KR.

Ther Drug Monit. 2015 Feb;37(1):110-8. doi: 10.1097/FTD.0000000000000113.

41.

Total and free thyroxine and triiodothyronine: measurement discrepancies, particularly in inpatients.

Jonklaas J, Sathasivam A, Wang H, Gu J, Burman KD, Soldin SJ.

Clin Biochem. 2014 Sep;47(13-14):1272-8. doi: 10.1016/j.clinbiochem.2014.06.007. Epub 2014 Jun 14.

42.

Spinal metastases due to thyroid carcinoma: an analysis of 202 patients.

Kushchayeva YS, Kushchayev SV, Carroll NM, Felger EA, Links TP, Teytelboym OM, Bonichon F, Preul MC, Sonntag VK, Van Nostrand D, Burman KD, Boyle LM.

Thyroid. 2014 Oct;24(10):1488-500. doi: 10.1089/thy.2013.0633. Epub 2014 Aug 1.

PMID:
24921429
43.

Thyroid cancer and other thyroid disorders.

Burman KD, Jonklaas J.

Endocrinol Metab Clin North Am. 2014 Jun;43(2):xvii-xviii. doi: 10.1016/j.ecl.2014.03.002. Epub 2014 Apr 4. No abstract available.

PMID:
24891181
44.

Management of recurrent cervical papillary thyroid cancer.

Goyal RM, Jonklaas J, Burman KD.

Endocrinol Metab Clin North Am. 2014 Jun;43(2):565-72. doi: 10.1016/j.ecl.2014.02.014. Review.

PMID:
24891178
45.

Current treatment modalities for spinal metastases secondary to thyroid carcinoma.

Kushchayeva YS, Kushchayev SV, Wexler JA, Carroll NM, Preul MC, Teytelboym OM, Sonntag VK, Van Nostrand D, Burman KD, Boyle LM.

Thyroid. 2014 Oct;24(10):1443-55. doi: 10.1089/thy.2013.0634. Epub 2014 Jul 23. Review.

PMID:
24827757
46.

Is poorly differentiated thyroid cancer poorly characterized?

Burman KD.

J Clin Endocrinol Metab. 2014 Apr;99(4):1167-9. doi: 10.1210/jc.2014-1549. No abstract available.

PMID:
24702015
47.

A 2013 survey of clinical practice patterns in the management of primary hypothyroidism.

Burch HB, Burman KD, Cooper DS, Hennessey JV.

J Clin Endocrinol Metab. 2014 Jun;99(6):2077-85. doi: 10.1210/jc.2014-1046. Epub 2014 Feb 14.

PMID:
24527720
48.

A diagnostic scoring system for myxedema coma.

Popoveniuc G, Chandra T, Sud A, Sharma M, Blackman MR, Burman KD, Mete M, Desale S, Wartofsky L.

Endocr Pract. 2014 Aug;20(8):808-17. doi: 10.4158/EP13460.OR.

PMID:
24518183
49.

3,3'-Diiodothyronine concentrations in hospitalized or thyroidectomized patients: results from a pilot study.

Jonklaas J, Sathasivam A, Wang H, Finigan D, Soldin OP, Burman KD, Soldin SJ.

Endocr Pract. 2014 Aug;20(8):797-807. doi: 10.4158/EP13453.OR.

50.

Repositioning therapy for thyroid cancer: new insights on established medications.

Kushchayeva Y, Jensen K, Burman KD, Vasko V.

Endocr Relat Cancer. 2014 May 6;21(3):R183-94. doi: 10.1530/ERC-13-0473. Print 2014 Jun. Review.

PMID:
24446492

Supplemental Content

Loading ...
Support Center